Fig. 5: miR-145 attenuates the macrophage M1 program by inhibiting SELL expression.

a Average FPKM values of the PBS-treated group and the miR-145 mimics-treated group (n = 3 per group). Box plots present the means (lines inside the boxes), the 1st and 3rd quartiles (bottom and top bounds of the boxes). b Volcano plot of DEGs (fold change >2, p value ≤ 0.05) between the PBS-treated group and the miR-145 mimics-treated group. c Potential target genes of miR-145 predicted by TargetScan. d Heatmap of potential differentially expressed target genes in the PBS- and miR-145 mimics-treated groups. e Correlation analysis between age and the relative mRNA expression of Sell in the WAT ATMs of humans of different ages. f Protein expression levels of iNOS in BMDMs treated with either scrambled or Sell siRNA (n = 3 independent experiments). g Protein expression levels of iNOS in BMDMs subjected to specific treatments (n = 3 independent experiments). h KEGG analysis of all genes in M1 macrophages treated with scrambled or Sell siRNA, with a focus on the top 20 categories that exhibited the most significant changes. i, j Western blot results for iNOS, p-NF-κB p65, NF-κB p65, p-IκBα, and IκBα in BMDMs subjected to certain treatments (n = 3 independent experiments). The data were presented as mean ± SEM. Statistical significance was assessed by two-sided Student’s t-test followed by Benjamini-Hochberg false discovery rate (FDR) test (b), two-sided Spearman’s correlation (e), two-sided Hypergeometric test with Fisher’s exact test (h). Scr (scrambled siRNA), Si-Sell (Sell siRNA), Sell-Ctrl (rAd-ZsGreen), Sell-OE (rAd-ZsGreen-mSell-3Flag), CU-T12-9 (an NF-κB agonist). See also Supplementary Fig. 7. Source data are provided as a Source Data file.